Table 3.

Extent of Sensitization among Nine Desensitized Patients

Patient No.	Pre-PP CPRA*		DSA HLA Specificity	Crossmatch Tests†	Additional Risk Factors	Donors Evaluated
	Class I	Class II				Related	Unrelated
1	44	0	B7	CDC−	child to mother	2 children	4
				vFCXM+		2 siblings
2	98	94	DP1	CDC−		1 sibling	1
				vFCXM±
3	47	0	A2	CDC−	child to mother	2 children	0
				vFCXM+
4	0	96	DR13, DR52, DQ6	FCXM+	multiple DSA	2 children	5
						2 siblings
5	63	99	DR16	FCXM+		1 child	5
						2 parents
						3 half-siblings
						2 cousins
6	0	99	DQ4	FCXM+		2 children	6
						3 siblings
7	55	92	A2	CDC+	DSA strength	2 siblings	0
				Titer 8		2 parents
8	98	0	A3, B27	FCXM+	child to mother	3 children	1
						3 half-siblings
9	0	51	DR4, DR53	FCXM+	repeat DR4, DR53 mismatches	2 siblings	0
						2 parents
Mean	45.0	59.0
SD	38.9	46.6

PP indicates plasmapheresis; CPRA, calculated panel reactive antibody; CDC, complement-dependent cytotoxicity crossmatch; FCXM, flow cytometric crossmatch; vFCXM, virtual FCXM when actual crossmatch was not performed, but antibody levels were consistent with positive results.

^*The CPRA values were based on the frequencies for HLA antigens to which patients had antibodies at strengths consistent with positive complement dependent cytotoxicity and/or flow cytometric crossmatches. Accessed from: http://optn.transplant.hrsa.gov/resources/professionalResources.asp?index=78, CPRA Calculator.

^†Crossmatch results correlate with the following median fluorescence values (MFI) from the solid-phase immunoassays: FCXM+ on phenotype panels ≥5000; FCXM+ on single-antigen panels ≥10-15,000 MFI; positive complement-dependent cytotoxicity crossmatch (CDC+) ≥10,000 on a phenotype panel.